Description: It is not uncommon for EU Sponsors to initiate human trials locally and then expand into the United States. This session will highlight the difference in clinical development requirements between the US and the European Union Member States. Attendees will gain insight into common issues that delay the initiation of studies in the United States.
Learning Objectives:
Understand the major differences that have the potential to delay study start at their US sites.
Create development timelines that reasonably reflect what is likely to happen in the US.
